Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/17250
ชื่อเรื่อง: Effects of pharmacist interventions on heart failure outcomes: A systematic review and meta-analysis
ผู้แต่ง: Arunmanakul P.
Kengkla K.
Chaiyasothi T.
Phrommintikul A.
Ruengorn C.
Permsuwan U.
Thakkinstian A.
Page R.L.
II
Munger M.A.
Nathisuwan S.
Chaiyakunapruk N.
Keywords: beta adrenergic receptor blocking agent
dipeptidyl carboxypeptidase inhibitor
mineralocorticoid antagonist
adult
aged
all cause mortality
Article
controlled study
disease duration
female
heart failure
heart failure with reduced ejection fraction
heart left ventricle ejection fraction
hospitalization
human
major clinical study
male
medication therapy management
mental health
meta analysis
outcome assessment
patient compliance
pharmacist
quality of life
randomized controlled trial (topic)
Short Form 36
systematic review
วันที่เผยแพร่: 2021
บทคัดย่อ: Heart failure (HF) patients tend to have multiple comorbidities resulting in complex therapy regimens and medication adherence issues. Nevertheless, the evidence of pharmacists' contributions to improving clinical outcomes in HF is limited. To assess the impact of pharmacist intervention on all-cause hospitalization, mortality, and quality of life (QoL) in HF) patients. A systematic search of PubMed, Embase, the Cochrane Central Register of Controlled Trials, Scopus, and CINAHL was performed up to April 30, 2020. Randomized controlled trials (RCTs) evaluating pharmacist interventions compared with usual care in adult HF patients were selected. Data were extracted independently by two authors. Random effects meta-analysis models were used to pool treatment effects and confidence intervals (CIs). Twenty-nine trials identified 6965 predominantly HF with reduced ejection fraction (HFrEF) patients. The average age was 72.0 years (interquartile range [IQR] 66.0-76.0) and 48% were men (IQR 40.0%-68.0%). The majority were New York Heart Association (NYHA) Functional class (FC) II-III with median left ventricular ejection fraction (LVEF) of 38.5% (IQR 34.5%-49.5%). Pharmacist interventions were associated with a significant reduction of all-cause mortality (risk ratio [RR] 0.72; 95% CI 0.58-0.89; P = 0.003) and all-cause hospitalizations (RR 0.87; 95% CI 0.77-0.99; P = 0.041). A significant increase in the 36-item Short form Health survey (SF-36) on role physical (Mean deviation [MD], 8.5; 95% CI, 1.00 to 16.01, P = 0.026) and mental health (MD, 7.49; 95% CI, 3.88 to 11.10, P < 0.001) were observed. In addition, a significant improvement in Minnesota Living with Heart Failure Questionnaire score was observed (MD -3.55; 95% CI -6.28 to −0.82; P = 0.01). Pharmacist interventions in patients with HF significantly reduced all-cause mortality and hospitalizations and improved QoL. Integration of a pharmacist into a HF care team or care pathway should be strongly considered as an important element of a multidisciplinary team. © 2021 Pharmacotherapy Publications, Inc.
URI: https://ir.swu.ac.th/jspui/handle/123456789/17250
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85105603083&doi=10.1002%2fjac5.1442&partnerID=40&md5=b51cccec129996b6fe68e5ba3177b6fa
ISSN: 25749870
Appears in Collections:Scopus 1983-2021

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.